Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005994 · ClinicalTrials.gov registry record · NA

Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy

A NA study of Unspecified Adult Solid Tumor, Protocol Specific and Nausea and Vomiting, sponsored by University of Rochester.

Completed
Registry status
NA
Development phase
4
Study locations

NCT00005994 is a NA study of Unspecified Adult Solid Tumor, Protocol Specific and Nausea and Vomiting that has completed, run by University of Rochester. The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005994, a NA study of Unspecified Adult Solid Tumor, Protocol Specific and Nausea and Vomiting, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
NA
Development phase
4
Study locations

Study Summary

RATIONALE: Patient education may improve the effectiveness of ondansetron in preventing nausea and vomiting in patients receiving chemotherapy. PURPOSE: This randomized clinical trial is studying how well patient education works in preventing nausea and vomiting in cancer patients receiving chemotherapy.

Interventions

  • DRUG ondansetron

Study Locations (4)

New York

  • University of Rochester Cancer Center - Rochester
  • CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C. - Syracuse

New Jersey

  • Hackensack University Medical Center - Hackensack

North Carolina

  • CCOP - Southeast Cancer Control Consortium - Winston-Salem

Trial Details

FieldValue
Start Date 2000-08
Est. Completion 2001-07
Phase NA

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT00005994

The ClinicalTrials.gov registry entry for NCT00005994 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which ondansetron is the first listed.

NCT00005994 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00005994 about?

NCT00005994 is a clinical study titled "Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy". RATIONALE: Patient education may improve the effectiveness of ondansetron in preventing nausea and vomiting in patients receiving chemotherapy. PURPOSE: This randomized clinical trial is studying how well patient education works in preventing nausea and vomiting in cancer patients receiving chemoth...

What is the current status of trial NCT00005994?

This trial is currently completed. It is a NA study. The study started on 2000-08. Estimated completion is 2001-07.

What conditions does trial NCT00005994 study?

This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Nausea and Vomiting.

What interventions are being tested in trial NCT00005994?

The interventions under investigation include: ondansetron (DRUG).

Who is sponsoring clinical trial NCT00005994?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005994 being conducted?

This trial has 4 study locations across New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.